Australia's Memphasys soars on upbeat trial results for sperm selection device

Memphasys

24/03/2025 03:03

** Memphasys MEM.AX soars as much as 57.1% to A$0.011, set for biggest intraday gain since August 18, 2022

** Stock hits highest since January 6

** Medical devices maker reports positive clinical trial results for its Felix sperm selection system

** Says results exceed industry benchmarks in sperm selection for assisted reproductive technology

** Stock logs busiest trading day since October 2018, with ~50.3 mln shares traded vs 30-day avg of ~1.8 mln

** MEM last up ~43%, extends YTD gains to 25%

 (Reporting by Aaditya Govind Rao in Bengaluru)

 ((Aaditya.govindrao@thomsonreuters.com;))